West Pharmaceutical Services Financial Model
Medical Devices Company Financials Example (Free Excel Download)
West Pharmaceutical Services is a leading global manufacturer of packaging components and delivery systems for injectable drugs and healthcare products.
professionals from Deloitte
Used by professionals from
About this model
This model provides a comprehensive equity valuation and scenario analysis framework to determine the intrinsic value of West Pharmaceutical Services (WST) based on its exposure to high-value product (HVP) components, biologics growth, and GLP-1 auto-injector adoption.
West Pharmaceutical Services is a leading global manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The company designs and produces elastomer-based components, seals, and auto-injector systems that are critical to the safe and effective delivery of biologics, vaccines, and small-molecule drugs.
Business segments include:
- Proprietary Products (approximately 80% to 82% of total revenue)
- Contract-Manufactured Products (approximately 18% to 20% of total revenue)
Key geographies are split with approximately 55% of revenue generated from international markets and 45% from the United States. The business model is asset-heavy due to precision manufacturing requirements, but it benefits from highly recurring revenue because its components are typically specified directly into a customer's regulatory filings (such as FDA approvals), creating massive switching costs. West holds a dominant competitive position and market share in elastomer packaging, competing primarily with Stevanato Group, Gerresheimer, and AptarGroup. Recent major events include a period of customer inventory destocking in 2023 and 2024, followed by a return to strong organic growth in 2025 driven by the rapid adoption of GLP-1 weight-loss drugs and new Annex 1 regulatory standards requiring higher-quality packaging.
The downloadable West Pharmaceutical Services financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsWest Pharmaceutical Services financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.83B | $2.89B | $2.95B | $2.89B | $3.07B |
| Gross profit | $1.18B | $1.14B | $1.13B | $998.5M | $1.10B |
| Operating income | $752.3M | $734.0M | $676.0M | $569.9M | $584.9M |
| Net income | $661.8M | $585.9M | $593.4M | $492.7M | $493.7M |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for West Pharmaceutical Services
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Proprietary Products
- Segment name: Proprietary Products
- Revenue driver formula: Injectable Drug Volume x Blended Average Selling Price (driven by mix shift to High-Value Products)
- Historical growth rate: 4% to 8% organic CAGR, with recent quarters accelerating to high-single digits.
- Key growth levers and headwinds: Growth is heavily driven by the transition from standard packaging to High-Value Products (HVP) like NovaPure, FluroTec, and Westar, which command significant price premiums. The explosion of GLP-1 receptor agonists and biologics requires advanced self-injection device platforms. Headwinds include periodic customer inventory destocking and generic drug volume declines.
- Pricing dynamics: Contractual with high pricing power. Because the cost of the packaging is a fraction of the final drug price but critical to safety, customers are relatively price-insensitive.
- Revenue recognition notes: Recognised primarily at a point in time when control of the products transfers to the customer (typically upon shipment).
- Seasonality: Relatively balanced across the year, though Q4 often sees a slight uptick due to year-end pharmaceutical purchasing cycles.
Contract-Manufactured Products
- Segment name: Contract-Manufactured Products
- Revenue driver formula: Number of Active Manufacturing Contracts x Average Revenue per Contract
- Historical growth rate: 1% to 3% organic CAGR.
- Key growth levers and headwinds: Driven by demand for self-injection devices for obesity and diabetes, offset by declines in legacy healthcare diagnostic devices.
- Pricing dynamics: Cost-plus or fixed-price contracts. Margins are significantly lower than the Proprietary segment because West does not own the underlying intellectual property of the devices.
- Revenue recognition notes: Recognised over time or at a point in time depending on whether the manufactured product has an alternative use and if West has an enforceable right to payment for performance completed to date.
- Seasonality: Minimal seasonality; driven by specific customer product launch timelines.
Cost Structure
Variable Costs / COGS
- COGS includes raw materials (synthetic elastomers, plastics, aluminium), direct manufacturing labour, facility overhead, and depreciation of manufacturing equipment.
- Consolidated gross margin has historically ranged from 36% to 39%.
- Key input costs include petroleum-based raw materials and energy costs.
- COGS scales with a degree of operating leverage. As the mix shifts toward HVP, gross margins expand because the incremental cost to produce a coated or washed stopper (HVP) is far lower than the price premium charged.
Operating Expenses
- R&D: Typically runs at 1.5% to 2.0% of revenue. It covers the development of new elastomer formulations, containment solutions, and advanced auto-injector mechanisms.
- SG&A: Typically 11% to 13% of revenue. This includes sales, marketing, and general administrative headcount, as well as enterprise IT investments.
- Depreciation & Amortisation: Embedded primarily in COGS (for manufacturing PP&E) and SG&A.
- Stock-Based Compensation: Runs at approximately 1.0% to 1.5% of revenue.
- Restructuring / one-time charges: Infrequent, though occasional facility consolidation costs or temporary disruption costs (such as the 2025 Arizona facility disruption) occur.
Margin Profile
- Gross margin: 36% to 39%. Proprietary Products operate at 40% to 43% gross margin, while Contract-Manufactured Products operate at 12% to 17% gross margin.
- Operating margin: 21% to 23%.
- Net margin: 16% to 18%.
- Margins are generally expanding over the long term due to the mix shift toward HVP, which carries structurally higher profitability.
Balance Sheet Structure
- Total assets are approximately $3.5 billion to $4.0 billion.
- Key asset categories are Property, Plant, and Equipment (PP&E) and Inventory. PP&E is the largest line item due to the capital-intensive nature of precision manufacturing and cleanroom facilities.
- Goodwill & intangibles represent a small portion of total assets (typically under 10%), as West relies primarily on organic growth rather than transformational M&A.
- Working capital profile:
- Days Sales Outstanding (DSO): 45 to 55 days.
- Days Inventory Outstanding (DIO): 70 to 90 days. High inventory is required to ensure zero stockouts for critical pharmaceutical customers.
- Days Payable Outstanding (DPO): 35 to 45 days.
- Net working capital is positive and consumes cash during periods of high growth.
- PP&E consists of global manufacturing facilities, cleanrooms, and specialised moulding equipment. Useful lives range from 10 to 40 years for buildings and 3 to 15 years for machinery.
- Right-of-use assets are present but not a dominant feature of the balance sheet compared to owned manufacturing sites.
Capital Expenditure & Investment
- Capex as a percentage of revenue typically ranges from 8% to 12%. In FY2025, capex was $285.9 million (approximately 9.3% of revenue).
- Growth capex represents the majority of recent spend, specifically targeted at expanding HVP manufacturing capacity and commercial drug handling operations (such as the Dublin facility).
- Capitalised software costs are minimal compared to physical plant investments.
- M&A pattern is strictly bolt-on. The company occasionally acquires small technology firms or buys out joint venture partners (such as increasing ownership in Daikyo), but organic growth is the primary engine.
Debt & Capital Structure
- Total debt is very low, typically under $300 million, resulting in a net cash position or near-zero net debt.
- Debt/EBITDA ratio is consistently below 0.5x.
- Key debt instruments include a revolving credit facility and senior unsecured notes.
- Interest rate profile is highly manageable given the low debt balances, with interest income on cash often offsetting interest expense.
- The share repurchase programme is highly active. West repurchased $560 million in stock in 2024 and $134 million in 2025.
- Dividend policy features a low payout ratio (typically under 15%) and a low yield (under 0.5%), but the company has a long history of consistent annual dividend increases.
Cash Flow Characteristics
- Operating cash flow conversion is excellent, with OCF routinely exceeding Net Income (OCF was $754.8 million in FY2025).
- Free cash flow margin typically ranges from 10% to 15% (FCF was $468.9 million in FY2025).
- Major non-cash items bridging net income to OCF include depreciation, amortisation, and stock-based compensation.
- Working capital is a use of cash during expansion phases, particularly as inventory builds are required to support new HVP product launches.
- Capex intensity is currently elevated to support GLP-1 and biologics demand but is expected to normalise slightly as major facility build-outs complete.
- The effective tax rate typically ranges from 17% to 19%, benefiting from stock-based compensation tax benefits and foreign earnings mix.
Sheet Structure
- Assumptions: Contains all hardcoded inputs for macroeconomic drivers, segment growth rates, margin profiles, working capital days, capex percentages, and WACC.
- Revenue & Gross Margin: Builds revenue and COGS from the bottom up for the two reported segments (Proprietary Products and Contract-Manufactured Products).
- Income Statement: Consolidated view linking revenue and gross profit from the segment sheet, subtracting SG&A, R&D, and interest to arrive at Net Income and EPS.
- Balance Sheet: Standard presentation of Assets, Liabilities, and Shareholders' Equity. Must balance in all periods.
- Cash Flow Statement: Indirect method starting with Net Income, adjusting for non-cash items, changes in working capital, capex, debt issuance/repayment, and shareholder returns.
- Working Capital & Capex: Schedules for accounts receivable, inventory, accounts payable, and a PP&E rollforward (beginning balance plus capex minus depreciation).
- Debt Schedule: Tracks revolver and term debt balances, calculating interest expense based on average balances and interest income on cash.
- DCF Valuation: Calculates Unlevered Free Cash Flow, applies the discount rate, calculates the terminal value, and bridges enterprise value to equity value per share.
Key Financial Relationships
- Proprietary Products Revenue = Prior Year Proprietary Revenue * (1 + Proprietary Organic Growth Rate)
- Contract-Manufactured Revenue = Prior Year CM Revenue * (1 + CM Organic Growth Rate)
- Consolidated Net Sales = Proprietary Products Revenue + Contract-Manufactured Revenue
- Proprietary COGS = Proprietary Products Revenue * (1 - Proprietary Gross Margin %)
- Contract-Manufactured COGS = Contract-Manufactured Revenue * (1 - Contract-Manufactured Gross Margin %)
- Consolidated Gross Profit = Proprietary Revenue - Proprietary COGS + Contract-Manufactured Revenue - Contract-Manufactured COGS
- SG&A Expense = Consolidated Net Sales * SG&A % of Revenue
- R&D Expense = Consolidated Net Sales * R&D % of Revenue
- Operating Profit = Consolidated Gross Profit - SG&A Expense - R&D Expense
- Accounts Receivable = (Consolidated Net Sales / 365) * DSO
- Inventory = (Consolidated COGS / 365) * DIO
- Accounts Payable = (Consolidated COGS / 365) * DPO
- Free Cash Flow = Cash from Operations - Capital Expenditures
- Ending Shares Outstanding = Beginning Shares Outstanding - (Share Repurchase Amount / Average Share Price)
Cross-Sheet Dependencies
- The Assumptions sheet feeds all other sheets. No hardcodes should exist outside this sheet.
- The Revenue & Gross Margin sheet calculates the top-line and direct costs, feeding directly into the Income Statement.
- The Income Statement generates Net Income, which is the starting point for the Cash Flow Statement and feeds Retained Earnings on the Balance Sheet.
- The Working Capital & Capex sheet calculates changes in NWC and depreciation, which feed the Cash Flow Statement and the Balance Sheet (PP&E and working capital line items).
- The Debt Schedule uses cash flow deficits/surpluses from the Cash Flow Statement to draw down or pay down the revolver, and feeds Interest Expense back to the Income Statement. This creates a circular reference that requires a toggle switch to break.
- The DCF Valuation pulls NOPAT and D&A from the Income Statement, Capex and NWC changes from the Cash Flow Statement, and current net debt from the Balance Sheet.
Sign Convention
- Revenues, asset balances, liability balances, and equity balances are entered and displayed as positive numbers.
- On the Income Statement, expenses (COGS, SG&A, R&D, Interest, Taxes) are calculated as positive numbers and subtracted to reach profit subtotals.
- On the Cash Flow Statement, cash inflows are positive and cash outflows (such as Capex, dividends, share repurchases, and working capital increases) are negative.
Things Most Likely to Go Wrong
- Applying a consolidated gross margin assumption instead of modelling the segments separately. The Proprietary segment has a gross margin near 42%, while Contract Manufacturing is near 15%. A mix shift changes the consolidated margin significantly.
- Failing to account for the massive impact of High-Value Products (HVP). HVP drives both top-line growth and gross margin expansion; the model must reflect margin expansion if Proprietary growth outpaces Contract Manufacturing.
- Underestimating capital expenditures. West is in a heavy investment cycle to build capacity for GLP-1 and biologics packaging. Capex should remain elevated in the near term before normalising.
- Overcomplicating the debt schedule. West operates with very little debt; the focus of the model should be on cash generation and share repurchases rather than complex leverage metrics.
- Ignoring foreign exchange impacts. With 55% of sales outside the US, currency fluctuations can swing reported revenue. The model should assume constant currency for future projections.
- Miscalculating inventory days. West must hold significant inventory to serve pharma clients; modelling a drastic reduction in DIO will artificially inflate projected free cash flow.
- Double-counting depreciation. Ensure D&A is properly allocated between COGS and operating expenses so that EBITDA reconciles correctly.
- Forgetting the share count reduction. West uses its substantial free cash flow to buy back stock consistently, which provides a steady tailwind to EPS.
Validation Checks
- Consolidated Gross Margin should remain between 36% and 40%. Flag if it falls outside this band.
- Proprietary Products should represent 80% to 85% of total revenue.
- Capex as a percentage of revenue should run between 8% and 11%.
- Operating cash flow must exceed Net Income in every projected year.
- The Balance Sheet must balance exactly: Total Assets minus (Total Liabilities + Shareholders' Equity) must equal zero.
- Effective tax rate should remain between 17% and 19%.
- Debt/EBITDA should remain below 1.0x given the company's conservative balance sheet.
- Free Cash Flow margin should be between 12% and 18%.
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| Proprietary Products Revenue Growth | 6.5 | % | Reflects strong underlying demand for HVP and GLP-1 components, normalising after 2024 destocking. |
| Contract-Manufactured Revenue Growth | 2.5 | % | Historical average for this lower-growth, mature segment. |
| Proprietary Products Gross Margin | 41.5 | % | Based on recent historical averages and continued HVP mix shift. |
| Contract-Manufactured Gross Margin | 15.0 | % | Based on recent historical averages for the contract business. |
| SG&A as % of Revenue | 12.0 | % | Consistent with management guidance and historical run rates. |
| R&D as % of Revenue | 1.8 | % | Historical average required to maintain product innovation. |
| Days Sales Outstanding (DSO) | 50 | Days | Calculated from recent balance sheet receivables and revenue. |
| Days Inventory Outstanding (DIO) | 80 | Days | Calculated from recent balance sheet inventory and COGS. |
| Days Payable Outstanding (DPO) | 40 | Days | Calculated from recent balance sheet payables and COGS. |
| Capex as % of Revenue | 9.0 | % | Aligns with FY2025 actuals and FY2026 management guidance ($250M-$275M). |
| Effective Tax Rate | 18.0 | % | Historical average effective tax rate. |
| Annual Share Repurchases | 150 | $ Millions | Conservative estimate based on recent historical buyback activity. |
| Dividend Payout Ratio | 12.0 | % | Reflects the company's policy of steady, small dividend increases. |
| Cost of Debt | 4.5 | % | Estimated weighted average interest rate on current debt facilities. |
| WACC | 7.5 | % | Appropriate discount rate for a low-beta, highly stable healthcare supplier. |
| Terminal Growth Rate | 3.0 | % | Reflects long-term GDP growth plus a premium for the structural growth in biologics. |
Data Sources & Benchmarks
- Filings: SEC EDGAR for West Pharmaceutical Services (WST) 10-K and 10-Q filings. The Investor Relations page on westpharma.com provides earnings presentations and transcript data.
- Peers for Benchmarking: Stevanato Group (STVN), Gerresheimer AG (GXI.DE), AptarGroup (ATR), and Catalent (CTLT).
- Industry Data: IQVIA reports on global medicine spending and biologics pipelines; FDA approval databases for new injectable drugs.
- Consensus Estimates: FactSet or Bloomberg for forward-looking revenue and EPS consensus to validate model outputs against street expectations.
Sources
- West Pharmaceutical Services FY2025 10-K and Q4 2025 Earnings Release (February 2026).
- West Pharmaceutical Services FY2024 10-K and Q4 2024 Earnings Release (February 2025).
- West Pharmaceutical Services Q1 2025 Earnings Release (April 2025).
- Seeking Alpha Earnings Call Transcripts for WST.
- PitchBook company profile and financial summary for West Pharmaceutical Services.
Do more with the West Pharmaceutical Services model
Frequently asked
What does West Pharmaceutical Services (WST) do?+
West Pharmaceutical Services is a leading global manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The company designs and produces elastomer-based components, seals, and auto-injector systems essential for the safe and effective delivery of various pharmaceutical products.
What are the primary revenue drivers for West Pharmaceutical Services?+
West Pharmaceutical Services' revenue is primarily driven by its exposure to high-value product (HVP) components, the growth in biologics, and the adoption of GLP-1 auto-injectors. The business benefits from highly recurring revenue because its components are typically specified directly into customer regulatory filings, creating significant switching costs.
What is the typical capital expenditure as a percentage of revenue for West Pharmaceutical Services?+
Capital expenditure for West Pharmaceutical Services typically ranges from 8% to 12% of revenue, reflecting its asset-heavy business model due to precision manufacturing requirements. For example, in FY2025, capex was approximately 9.3% of revenue, with a significant portion allocated to expanding HVP manufacturing capacity.
What are the key profitability assumptions used in the financial model for West Pharmaceutical Services?+
The financial model for West Pharmaceutical Services assumes a Cost of Goods Sold (COGS) as a percentage of revenue at approximately 62.43%. Additionally, Selling, General, and Administrative (SGA) expenses are modeled at about 12.93% of revenue, contributing to the company's overall profitability profile.
What is the forecast horizon for the West Pharmaceutical Services financial model used for valuation?+
The financial model for West Pharmaceutical Services provides a comprehensive equity valuation and scenario analysis based on a forecast horizon from fiscal year 2026 through fiscal year 2030. This allows for a detailed assessment of the company's intrinsic value over a multi-year period.
Is there a downloadable financial model available for West Pharmaceutical Services (WST)?+
Yes, a downloadable Excel financial model is available for West Pharmaceutical Services (WST). This general corporate model offers a framework for equity valuation and scenario analysis, incorporating key assumptions about the company's financials and business drivers.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Medical Devices Company Financial Models
Browse another company in the same sector.
Abbott Laboratories
Abbott Laboratories is a diversified global healthcare company that discovers, develops, manufactures, and sells a broad line of healthcare products.
Align Technology
Align Technology is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry.
Baxter International
Baxter International Inc.
Becton Dickinson
Becton, Dickinson and Company (BD) is a leading global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products.
Boston Scientific
Boston Scientific is a global developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties.
Cooper Companies
The Cooper Companies, Inc.
Dexcom
Dexcom is a medical device company focused on the design, development, and commercialisation of continuous glucose monitoring systems that provide real-time glucose readings for people with diabetes, replacing traditional fingerstick testing.
Edwards Lifesciences
Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease.
Explore more Healthcare financial model templates.
